GSK PLC on Tuesday said that its investigational targeted inhibitor linerixibat demonstrated sound results for a treatment of relentless itch.

The London-based pharmaceutical company said that in cholestatic pruritus, also known as relentless itch, in primary biliary cholangitis, an autoimmune disease known as PBC, linerixibat showed a statistically significant improvement over 24 weeks when compared to a placebo.

Linerixibat is an investigational targeted inhibitor of the ileal bile acid transporter.

‘Linerixibat has the potential to be the first global therapy specifically developed to treat itch in PBC. These positive data suggest that it could have a place in supporting patients whose quality of life is significantly affected in multiple ways by persistent itching,’ said Kaivan Khavandi, global head at Respiratory/Immunology research & development at GSK.

Citing medical studies, GSK said people diagnosed with PBC will reach 510,000 by 2030, with more than 240,000 people experiencing relentless itch requiring treatment.

GSK shares were 0.3% lower at 1,306.45 pence each on Tuesday morning in London.

Copyright 2024 Alliance News Ltd. All Rights Reserved.